Latest Articles

Publication Date
Mimics of primary ovarian cancer and primary peritoneal carcinomatosis - A pictorial review.

Numerous conditions can mimic ovarian malignancy. Identifying the origin of a pelvic mass or disseminated peritoneal abnormality on imaging is important to ensure that the patient receives optimal management by …

Published: July 9, 2024, midnight
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma - OncLive

ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma OncLive

Published: June 20, 2024, 7 a.m.
Endometriosis increases risks for ovarian, endometrial cancers - Healio

Endometriosis increases risks for ovarian, endometrial cancers Healio

Published: June 7, 2024, 7 a.m.
FDA grants breakthrough designation for ovarian cancer liquid biopsy - TechTarget

FDA grants breakthrough designation for ovarian cancer liquid biopsy TechTarget

Published: May 31, 2024, 7 a.m.
For some endometriosis-related ovarian cancers, timing is everything - Medical Xpress

For some endometriosis-related ovarian cancers, timing is everything Medical Xpress

Published: May 28, 2024, 7 a.m.
Estrogen-Only Therapy for Menopausal Symptoms Increases Ovarian Cancer Risk - Medpage Today

Estrogen-Only Therapy for Menopausal Symptoms Increases Ovarian Cancer Risk Medpage Today

Published: May 24, 2024, 7 a.m.
Mayo scientists explore swabs for early endometrial, ovarian cancer detection - Mayo Clinic

Mayo scientists explore swabs for early endometrial, ovarian cancer detection Mayo Clinic

Published: May 23, 2024, 7 a.m.
Genetic alteration of mRNA editing enzyme APOBEC3B in the pathogenesis of ovarian endometriosis.

What are the specific genetic alterations and associated network in endometriotic cells responsible for the disease pathogenesis?

Published: May 23, 2024, midnight
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewswire

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous …

Published: May 20, 2024, 7 a.m.
Plaintiffs Seek To Dismiss Hair Relaxer Lawsuits Involving Women Not Diagnosed with Uterine, Endometrial or Ovarian Cancer - AboutLawsuits.com

Plaintiffs Seek To Dismiss Hair Relaxer Lawsuits Involving Women Not Diagnosed with Uterine, Endometrial or Ovarian Cancer AboutLawsuits.com

Published: May 15, 2024, 8:32 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!